Key result
Mefenamic acid and DIDS bind an extracellular KCNE1/KCNQ1 pocket to shift IKs channel activation ~106 mV.
Why the study?
Pharmacological IKs activators are of therapeutic interest for IKs loss-of-function disorders, but why one group of chemical activators is only active in the presence of the KCNE1 subunit required investigation.
Effect estimate: ΔV1/2 -105.7 mV
Absolute Event Rate: -80.3% vs 25.4%
p-value: p=<0.0001
The study identifies a generalized extracellular binding pocket for IKs activators on the KCNQ1/KCNE1 complex, providing a mechanistic basis for enhanced IKs currents and a map for future drug design.
Provides structural template for IKs activator design; hypothesis-generating for human arrhythmia therapy.
The cardiac IKs ion channel comprises KCNQ1, calmodulin, and KCNE1 in a dodecameric complex which provides a repolarizing current reserve at higher heart rates and protects from arrhythmia syndromes that cause fainting and sudden death. Pharmacological activators of IKs are therefore of interest both scientifically and therapeutically for treatment of IKs loss-of-function disorders. One group of chemical activators are only active in the presence of the accessory KCNE1 subunit and here we investigate this phenomenon using molecular modeling techniques and mutagenesis scanning in mammalian cells. A generalized activator binding pocket is formed extracellularly by KCNE1, the domain-swapped S1 helices of one KCNQ1 subunit and the pore/turret region made up of two other KCNQ1 subunits. A few residues, including K41, A44 and Y46 in KCNE1, W323 in the KCNQ1 pore, and Y148 in the KCNQ1 S1 domain, appear critical for the binding of structurally diverse molecules, but in addition, molecular modeling studies suggest that induced fit by structurally different molecules underlies the generalized nature of the binding pocket. Activation of IKs is enhanced by stabilization of the KCNQ1-S1/KCNE1/pore complex, which ultimately slows deactivation of the current, and promotes outward current summation at higher pulse rates. Our results provide a mechanistic explanation of enhanced IKscurrents by these activator compounds and provide a map for future design of more potent therapeutically useful molecules.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) studied IKs channel function. Mefenamic acid and DIDS vs. Control (absence of drug) was evaluated on Change in V1/2 of activation (ΔV1/2) for WT EQ in the presence of 100 µM mefenamic acid (ΔV1/2 -105.7 mV, p=<0.0001). Mefenamic acid and DIDS bind to a generic extracellular pocket formed by KCNE1 and KCNQ1 subunits, shifting the voltage dependence of IKs channel activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: